Extended data table 2. Safety parameters measured in all groups at baseline and after two weeks of treatment.

	Placebo		Pasteurized Akk -1010		Alive Akk -1010
Safety parameters	Baseline	Safety	Baseline	Safety	Baseline	Safety
Systolic blood pressure (mm Hg)	145,92 ± 13,94	134,92 ± 18,53	150,38 ± 12,52	134,85 ± 19,20*	138,00 ± 17,97	138,21 ± 16,84
Diastolic blood pressure (mm Hg)	94,92 ± 13,97	90,31 ± 9,89	101,92 ± 11,28	91,77 ± 17,19	95,57 ± 19,29	92,43 ± 12,49
C-reactive protein (mg/dl)	5,23 ± 5,38	4,78 ± 3,14	7,77 ± 9,12	9,46 ± 11,33	4,07 ± 4,43	5,48 ± 5,860
White Blood cells (103/μl)	6,00 ± 1,08	6,78 ± 1,48*	6,47 ± 1,66	7,33 ± 1,54*	6,74 ± 1,28	7,5 ± 1,53*
Prothrombin time (sec)	11,48 ± 0,69	11,35 ± 0,62	11,66 ± 0,89	11,5 ± 0,83	11,47 ± 0,67	11,38 ± 0,70
Alanine aminotransferase activity (U/L)	23,38 ± 10,4	24,54 ± 10,94	47,62 ± 38,01	44,85 ± 35,59	33,43 ± 12,89	35,43 ±13,44
Aspartate aminotransferase activity (U/L)	18,92 ± 5,78	18,77 ± 4,80	32,92 ± 31,45	35,23 ± 41,2	22,07 ± 7,08	23,64 ± 7,06
γ-Glutamyltransferase activity (U/L)	25,92 ± 16,59	29,38 ± 24,77	50,85 ± 32,93	47,85 ± 27,82	39,64 ± 21,1	40,86 ± 20,08
Urea (mg/dl)	33,69 ± 7,76	30,77 ± 6,76	30,38 ± 3,10	35,69 ± 13,38	32,21 ± 6,71	32,64 ± 7,33
Creatinine (mg/dl)	0,84 ± 0,15	0,83 ± 0,17	0,82 ± 0,13	0,84 ± 0,14	0,86 ± 0,14	0,90 ± 0,11
Glomerular filtration rate (ml min-1 1,73m-2)	84,15±16,09	86 ± 13,99	85,69 ± 14,13	82,92 ± 12,28	88,79 ± 15,84	82,14 ± 12,98
Creatine kinase activity (U/L)	114,3 ± 59,88	100,9 ± 58,96	152 ± 81,47	123,1 ± 63,19	118,4 ± 50,57	165 ± 175,8
Lactate dehydrogenase activity (UI/L)	177,4 ± 23,01	170,2 ± 21,46	193,9 ± 21,01	189,5 ± 39,34	190,9 ± 45,51	189,7 ± 32,22

This table includes all participants that proceeded to the safety visit: Placebo n=13, Pasteurized n=13, Alive n=14. Data are expressed as mean ± SD. Non-parametric two-tailed Wilcoxon matched-pairs signed ranks tests were performed to verify changes from baseline in each group.

^*Significant difference from baseline value (P < 0.05)